Quick answer: If your practice buys expensive inputs before knowing what you'll get paid — specialty drugs, radiopharmaceuticals, implants, biologics — you're running a manufacturing operation disguised as a medical practice. We used AI to analyze 418 high-cost procedures across five centers and found that 21% of paid encounters still lost money. Not denied. Not pending. Paid — and unprofitable. The gap between the best and worst payer was 9:1 on the same procedure. The data was already in their billing system. Nobody had ever looked at it this way.

Key Takeaway: When your input cost is $2,940 per procedure, the difference between a payer that reimburses 239% and one that reimburses 26% isn't a billing nuance — it's the difference between a $4,082 profit and a $2,164 loss on the same scan, same staff, same day. Twenty-one percent of paid encounters in our analysis lost money. That's not a collections problem. It's a scheduling problem. And most practices don't discover it until cash gets tight enough to panic.

The $2,940 Question Every Practice Owner Should Be Asking

You order a specialty drug. It costs $2,940 per dose. Your staff prepares it, administers it, documents it, bills it. Forty-five days later — maybe sixty — you find out what the payer decided it was worth.

This is not an unusual workflow. It's Tuesday.

If you run an imaging center using specialty radiopharmaceuticals, an infusion center administering biologics, a surgery center placing implants, or a dental practice doing full-arch restorations — you know this feeling. You're buying raw materials at retail prices and selling finished procedures at prices you don't control, to customers who pay whenever they feel like it.

Every other manufacturing business on earth would call this insane. In healthcare, we call it operations.

The question most practice owners never ask — because their accounting doesn't surface it — is brutally simple: on a per-encounter basis, which procedures make money and which ones lose it?

Not "how's our revenue this month." Not "what's our payer mix." The actual math: input cost plus labor plus overhead, compared to the check that actually arrived, for each individual encounter.

We ran that math. The answers were ugly.

Same Procedure, Same Staff, 9:1 Reimbursement Gap

A five-location imaging group asked us to analyze their specialty procedure economics. They perform a high-cost scan using a drug that runs approximately $2,940 per dose. The scan itself requires the same staff, same equipment, same time — regardless of who's paying.

We pulled 418 encounters across all five centers and mapped each one to its actual reimbursement.

Here's what the payer-level data looked like:

Same drug. Same scan. Same staff. Same 45-minute appointment slot.

Payer A generates $4,082 in margin. Payer G generates a $2,164 loss.

That's a $6,246 swing — on the same procedure performed by the same technologist in the same room on the same day.

The practice wasn't tracking this. Their P&L showed "specialty scan revenue" as a single line. It looked fine. Aggregate revenue was growing. But buried inside that growth was a payer mix slowly tilting toward the bottom of the table.

They were manufacturing a product that lost money — and the more they made, the worse it got.

This isn't unique to imaging. If you're an infusion center buying biologics that cost $3,000-$8,000 per dose, a surgery center placing implants at $2,500-$15,000 each, or a veterinary practice performing orthopedic procedures with $1,200 hardware kits — your version of this table exists. You just haven't built it yet.

21% of Paid Procedures Still Lost Money

Here's the number that stops people mid-sentence: 88 of 418 encounters — 21% — were paid and still lost money.

Not denied. Not in appeals. Not stuck in A/R. The payer processed the claim, cut the check, and the practice deposited it. The money arrived. It just wasn't enough.

This is a critical distinction. Most practice managers focus on denials and collections. Those are real problems. But this isn't a collections problem. Every one of these 88 encounters was collected successfully. The loss was locked the moment the patient was scheduled.

When Payer G authorized a specialty scan, the practice confirmed the appointment, ordered a $2,940 drug, prepped the room, staffed the slot, performed the procedure, billed it — and received $776.

That's a $2,164 loss that no amount of billing follow-up can fix. The claim was paid correctly. The contract paid what the contract said it would pay.

According to CMS reimbursement data, even Medicare's published rates for specialty procedures vary significantly by locality and procedure code. But the gap between commercial payers on the same CPT code in the same market? That's where the 9:1 spread lives.

The MGMA has been reporting for years that practice profitability increasingly depends on procedure-level economics, not just top-line volume. This data confirms it — violently.

Practices that schedule based on "we have an open slot" without knowing the per-encounter economics of that payer are running blind. They're filling the schedule with activity that feels productive and is unprofitable.

If your practice handles any high-cost input, you need to know: what percentage of your paid encounters actually lose money? If you've never asked that question, the answer is almost certainly not zero.

$697,000 in Cash You Can't Touch

Bad payer mix is only half the problem. The other half is timing.

Across the five centers, the group had $697,000 in outstanding receivables tied specifically to specialty scan encounters. That's cash they'd already spent — $2,940 per dose, times hundreds of encounters — sitting in payer processing queues.

That works out to roughly $14,223 per business day in capital deployed but not yet returned.

The best payer in their mix averaged 18 days to payment. The worst averaged 41 days. Same procedure. Same billing. Twenty-three days of float difference — on a $2,940 input.

When your input cost is $300, a 23-day float difference is annoying. When it's $2,940, it's a cash flow crisis that your P&L will never show you.

The group was funding this gap with a credit line. They didn't think of it as "financing our worst payers' slow payment habits." They thought of it as "managing cash flow." Same thing. Different level of anger when you see the math.

For any practice owner wondering where the cash went when the P&L says you're profitable — this is the disconnect. Profit is an accounting concept. Cash is what you can spend. And $697,000 was stuck in the space between.

The 7x Risk Multiplier

Traditional procedures — standard imaging, routine office visits, basic lab work — carry input costs between $50 and $500. Those have the same collection lag. The same payer variability. The same billing headaches.

But when your input cost jumps to $2,800-$6,500 per encounter, everything changes. The same operational imprecision that's tolerable at $300 becomes existential at $3,000.

This is the math that should keep practice owners up at night. The operational workflow is identical — schedule, prep, perform, bill, wait. But the capital at risk per encounter is 7 to 16 times higher.

A traditional imaging center that gets sloppy about payer mix loses some margin. A specialty center that gets sloppy about payer mix can burn through $80,000 in six months without a single claim being denied.

This applies far beyond imaging. Infusion centers, surgery centers, specialty pharmacies, dental implant practices, even contractors buying materials before knowing the final job cost — anyone who commits capital before reimbursement is confirmed lives in this risk multiplier. The only question is what your number is.

The Assembly Line Fix

The fix isn't complicated. It's a mindset shift: treat every high-cost procedure as a manufactured product with a known cost, a known price (by payer), and a known margin.

Three questions every practice should answer before scheduling a high-cost encounter:

1. What does this procedure actually cost us — fully loaded? Drug or supply cost, plus staff time, plus allocated overhead. Not the charge. The cost.

2. What does this specific payer actually pay us? Not the fee schedule. The actual historical payment, net of adjustments, for this CPT code, from this payer, at this location.

3. Is the margin positive — and is it worth the capital commitment? A $200 margin on a $2,940 input that takes 41 days to collect might not be worth the slot. That same slot filled with a $4,082-margin encounter from Payer A is a different equation entirely.

This is assembly-line thinking. Every manufacturer on earth knows the cost of goods sold, the selling price by customer, and the margin per unit. Most medical practices don't — because their accounting system reports revenue in aggregate and their billing system reports collections by claim, and nobody connects the two.

We built a scoring framework that connects them. It maps every encounter to its input cost, payer-specific reimbursement, and actual margin. The practices that use it stop thinking in "volume" and start thinking in "profitable volume."

If you want to reach out and talk about what this framework looks like for your practice, we're happy to walk through it.

What Happened When AI Met the Billing Tracker

Here's what changed for the five-location group.

We connected our AI analysis engine to their existing billing data — the same data that had been sitting in their practice management system for years. No new software. No new integrations. No six-month implementation project. The data was already there.

In a single analysis pass across 418 encounters, the AI identified:

• $80,000+ in losses from paid-but-unprofitable encounters over six months
• The specific payers responsible for 89% of those losses (two payers accounted for nearly all of it)
• The specific locations where payer mix was most tilted toward loss-generating encounters
• The DSO gap by payer, quantified in daily capital cost
• Three scheduling changes that would eliminate 73% of the losses without reducing total volume

Nobody installed anything. Nobody migrated data. The practice had been generating this data for years — it just took an AI that could read billing records like a cost accountant instead of a revenue cycle manager.

The difference between knowing "we collected $1.2M on specialty scans" and knowing "41 of those scans lost us $2,164 each" is the difference between running a practice and running a profitable practice.

That shift — from aggregate reporting to per-encounter economics — is exactly what we do at Benefique. We're an AI-powered financial intelligence firm. We read the data your practice already generates and find the patterns hiding in plain sight.

Here's what Monday morning looks like after this analysis. The scheduler pulls up the day's high-cost procedures. Next to each appointment, there's a margin indicator — green, yellow, red — based on the payer contract and historical payment data. The practice manager reviews the week's mix: 80% green, 15% yellow, 5% red. She knows exactly how much capital goes out the door today, what comes back in 18 days versus 41, and what the week's expected margin is before a single patient walks in. No surprises. No end-of-quarter panic. No wondering where the cash went. She's running a business, not hoping for the best. And the owner? He's looking at the same dashboard from his phone, seeing the numbers he never had before — not because the data didn't exist, but because nobody had ever connected it this way.

That's the shift. Not more software. Not more staff. Just clarity on numbers that were already there.

If the data in this article sounds familiar — if you've been wondering why cash feels tight when revenue is growing — we should talk. One analysis. Your data. The answers are already in your system.

FAQ — High-Cost Procedure Economics

Does this only apply to imaging centers?

No. Any practice or business that commits significant capital to inputs before knowing the reimbursement amount faces this exact dynamic. Infusion centers buying biologics ($3,000-$8,000/dose), surgery centers purchasing implants ($2,500-$15,000), dental practices doing full-arch restorations ($4,000+ in materials), specialty pharmacies, even veterinary orthopedic practices — the math is identical. If your per-encounter input cost exceeds $1,000, you need per-encounter profitability analysis.

Can we just stop accepting patients from low-paying payers?

Possibly, but it's rarely that simple. Contract obligations, network participation requirements, and referral relationships all factor in. The better approach is awareness: know your per-encounter margin by payer, manage your mix intentionally, and make scheduling decisions with full economic visibility. Some practices find that limiting — not eliminating — low-margin payer volume to specific days or time slots preserves relationships while protecting margin.

What data do we need to run this analysis?

You likely already have it. You need: (1) procedure-level billing data with CPT codes, payer, and payment amounts; (2) your input cost per procedure (drug cost, implant cost, supply cost); and (3) your overhead allocation per encounter (staff time, room cost). Most practice management and billing systems contain items 1 and 2. Item 3 requires a per-unit cost analysis — which is exactly what our AI engine calculates.

How often should we review per-encounter profitability?

Monthly at minimum, weekly if your specialty procedure volume exceeds 20 encounters per week. Payer contracts change. Drug costs shift (specialty radiopharmaceuticals and biologics have seen 8-15% annual cost increases according to ASPE research). A payer that was profitable at last year's drug cost may not be profitable at this year's. Build the review into your monthly financial close, not your annual planning cycle.

Is this something our current accountant should be doing?

Most accounting firms report revenue and expenses in aggregate. Per-encounter profitability analysis requires connecting billing data, supply costs, and overhead allocation at the procedure level — a different skill set than traditional bookkeeping or tax preparation. This is the kind of analysis a fractional CFO or AI-powered financial intelligence platform is built for. If your accountant isn't delivering this view, it's not because they're bad at their job — it's because their tools weren't designed for it.

Gerrit Disbergen, EA, is the founder of Benefique Tax & Accounting in Davie, Florida. Benefique uses AI to analyze the financial data small businesses already generate — finding the patterns, gaps, and opportunities hiding in plain sight.

This article is for informational purposes only and does not constitute financial, tax, or medical billing advice. Specific reimbursement rates, payer policies, and procedure economics vary by market, contract, and specialty. Consult your financial advisor, billing specialist, and/or legal counsel before making changes to payer participation or scheduling practices.